Reuken, P A, Besteher, B, Finke, K et al. · European archives of psychiatry and clinical neuroscience · 2024 · DOI
This study followed over 1,000 people who had long-lasting symptoms after COVID-19 infection. Researchers found that about 31% of patients met the diagnostic criteria for ME/CFS at their first visit, but this dropped to 19% at a second visit months later. While patients reported feeling less fatigued and having fewer concentration problems over time, many continued to experience long-lasting symptoms that significantly affected their daily lives.
This study provides important real-world data showing that ME/CFS affects a substantial minority of COVID-19 survivors and that symptoms often persist long-term. Understanding the natural history and prevalence of post-COVID ME/CFS helps validate the condition as a significant clinical problem and may inform development of targeted interventions for this patient population.
This study does not establish causation or mechanisms linking COVID-19 to ME/CFS, nor does it evaluate the effectiveness of any specific treatments. The decline in self-reported symptoms does not necessarily mean patients have recovered functionally, and the discrepancy between self-report and structured screening suggests the true clinical picture may be more complex than perceived by patients alone.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →